Biopharma news, November 12, 2026
The most important drug and company news of November 12, 2026, ranked, each linked to its Gosset profiles.
Approval
Hengrui wins China approval for SHR-1918, first local ANGPTL3 antibody, in HoFH
Chinese regulators approved SHR-1918 for patients aged 12 and up with homozygous familial hypercholesterolemia. In a phase 3 trial of 54 patients, LDL cholesterol dropped 58.8% at week 12 versus a 5.5% rise on placebo, with the effect holding to week 24. Most side effects were mild.
Source types: SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.
Approval
China Approves Eravacycline 100 mg
China's National Medical Products Administration approved a new 100 mg strength of Everest Medicines' eravacycline product, 依嘉. The product's 50 mg strength was approved in China in 2023 for adults with complicated intra-abdominal infection. The company says the new strength may reduce preparation steps and drug waste for some patients and improve supply flexibility.
Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.
Licensing & partnership
Vor Bio adds RemeGen's long-acting BAFF/APRIL blocker RC298 to its license
Vor Bio widened its licence from RemeGen to cover RC298, an early-stage long-acting blocker of both BAFF and APRIL, for markets beyond Greater China. Vor pays about $56 million upfront, $10 million of it in cash, plus development milestones of as much as $300 million. RemeGen will lead phase 1 after a planned China IND in early 2027.
- DrugRC298
- CompanyRemeGen
- CompanyVor Bio
- TargetA Proliferation-Inducing Ligand
- TargetTumor necrosis factor ligand superfamily member 13B
Source types: Press release · SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.
Pivotal readout
Novartis's Rhapsido keeps working through one year in chronic inducible urticaria
In the phase 3 RemIND study, remibrutinib responses held to week 52 across three urticaria subtypes: 46.8% in symptomatic dermographism, 83.3% in cold urticaria and 58.2% in cholinergic urticaria. Patients switched to the drug from placebo after 24 weeks improved too. Safety matched earlier experience, and more regulatory filings are planned.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Approval
China approves Lilly's orforglipron, its first oral GLP-1 pill for weight management
Chinese regulators cleared orforglipron, a once-daily oral GLP-1 receptor agonist taken without food or water rules, for adult weight management. In ATTAIN-1 the top dose produced 12.4 kg average weight loss at 72 weeks, and 39.6% lost at least 15% versus 3.6% on placebo. Side effects were mostly mild gastrointestinal events during dose escalation.
Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.
Pivotal readout
Elafibranor normalizes ALP in most PBC patients in phase 3 ELSPIRE
In ELSPIRE, which enrolled primary biliary cholangitis patients with only mildly raised alkaline phosphatase, 85.3% on elafibranor reached normal ALP by week 52 versus 23.3% on placebo, and the drug was well tolerated. The data were shown at this year's AASLD liver congress and are being filed with regulators.
- Drugelafibranor
- TargetPeroxisome proliferator‑activated receptor alpha
- TargetPeroxisome proliferator-activated receptor gamma
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Pivotal readout
enGene to start detalimogene BLA by year-end after new LEGEND bladder cancer data
In the pivotal cohort of the phase 2 LEGEND trial in high-risk bladder cancer that no longer responds to BCG, 56% of 120 evaluable patients had a complete response, with a preliminary median duration of 10.1 months. Serious drug-related events hit 2% of patients. After meeting the FDA, enGene will begin its submission this year and aims to finish it by mid-2027.
- Drugdetalimogene voraplasmid
- CompanyenGene
- TargetInterleukin-12 receptor
- TargetRetinoic acid-inducible gene I protein
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Licensing & partnership
Blackstone commits up to $1.5 billion toward Pfizer's monthly GLP-1 berobenatide
Funds managed by Blackstone will pay as much as $1.5 billion by 2028 toward development of berobenatide, Pfizer's investigational once-a-month GLP-1 agonist. Blackstone earns payments only if the drug wins US approval for chronic weight management and meets sales targets, while Pfizer keeps ownership and control. Pfizer has 10 phase 3 trials under way or planned.
Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.
Pivotal readout
Innovent Gastric Cancer Data
At ESMO 2026, phase 3 G-HOPE-001 data showed median overall survival of 10.2 months with IBI343 versus 6.9 months with physician's choice in previously treated CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma. In a phase 1b study, first-line IBI363 plus XELOX achieved an 80% confirmed response rate and 12.4-month median progression-free survival in HER2-negative advanced disease. The expert describes precision targeting and combination treatment as promising directions, while noting that IBI363 remains at the proof-of-concept stage and needs phase 3 confirmation.
Source types: News article. Sources are available to Gosset users. Log in to see them.
Pivotal readout
DBV presents further VITESSE phase 3 results for VIASKIN peanut patch in young children
In the 654-child VITESSE trial in ages 4 to 7, 46.6% on the VIASKIN patch met the month-12 responder bar compared with 14.8% on placebo. New analyses showed milder reactions at food challenge and immune changes in line with allergen immunotherapy. Average adherence was 96.1%; the patch is still investigational.
Source types: Press release. Sources are available to Gosset users. Log in to see them.